Zydus Life Science

Market Cap

90,525.80 Cr

EPS

38.14

PE Ratio

19.98

Dividend Yield

0.33 %

Industry

Healthcare

52 Week High

1,324.30

52 Week low

855.10

PB Ratio

4.15

Debt to Equity

0.05

Sector

Pharmaceuticals

Investment Returns

In Long Term

In Short Term

1 Year

0.00%

2 Years

0.00%

3 Years

0.00%

4 Years

0.00%

5 Years

0.00%

Analyst Rating

- By Refinitiv from28 analysts

Analysts have suggested that investors can buy this stock

Buy42.86 %

42.86 %

Hold35.71 %

35.71 %

Sell21.43 %

21.43 %

Company News

View All News

Amneal Launches Generic Asacol and Receives FDA Approval for Generic Revlimid1 day ago

Amneal Pharmaceuticals, a competitor of Zydus Lifesciences, has launched a generic version of Mesalamine (Asacol) and received U.S. FDA approval for Lenalidomide (generic Revlimid). This development introduces new competition in the market for these medications.

USFDA Inspection at Zydus Lifesciences' API Manufacturing Site Concludes with No Observations4 days ago

Zydus Lifesciences announced that the U.S. Food and Drug Administration (USFDA) conducted a surveillance inspection at the company's Active Pharmaceutical Ingredient (API) manufacturing facility in Ambernath, Maharashtra. The inspection concluded with no observations, indicating a positive outcome for the company's manufacturing practices and quality control.

Peer Comparison Compare Peers on Screener

Competitors	LTP	Market Cap (₹ Cr.)	P/E Ratio	Revenue (₹ Cr.)	YoY Revenue Growth %	Net Profit (₹ Cr.)	YoY Profit Growth %	RSI
Sun Pharmaceutical	1,643.75	4,00,521.00	33.96	49,887.20	12.06	9,648	13.77	33.47
Divis Laboratories	5,757.05	1,58,705.10	76.76	8,184.00	0.89	1,600	64.53	44.68
Cipla	1,475.75	1,19,502.60	23.95	26,520.70	14.17	4,155	47.38	53.61
Torrent Pharmaceuticals	3,039.35	1,04,781.00	56.24	10,785.70	11.59	1,656	13.54	40.36
Dr Reddys Laboratories	1,151.80	97,705.30	18.19	28,905.40	12.36	5,578	1.69	29.40
Mankind Pharma	2,327.75	96,889.30	47.43	10,615.60	19.57	1,942	-16.38	37.28
Zydus Life Science	885.35	90,525.80	19.98	19,831.50	13.82	3,831	29.92	36.58
Lupin	1,905.35	90,213.10	31.47	20,141.50	19.94	1,936	38.82	33.59
Aurobindo Pharma	1,115.15	65,122.40	18.47	29,559.20	17.55	3,169	-10.04	40.08
Abbott	28,941.95	62,536.00	46.85	6,097.20	10.80	1,201	16.01	54.66

Growth Rate

Revenue Growth

13.82 %

Net Income Growth

91.39 %

Cash Flow Change

20.05 %

ROE

70.50 %

ROCE

52.01 %

EBITDA Margin (Avg.)

23.08 %

Quarterly Financial Results

Quarterly Financials	Mar 2015	Jun 2015	Sept 2015	Dec 2015	Mar 2016	Jun 2016	Sept 2016	Dec 2016	Mar 2017	Jun 2017	Sept 2017	Dec 2017	Mar 2018	Jun 2018	Sept 2018	Dec 2018	Mar 2019	Jun 2019	Sept 2019	Dec 2019	Mar 2020	Jun 2020	Sept 2020	Dec 2020	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024
Revenue	2,269	2,291	2,286	2,300	2,310	2,232	2,360	2,266	2,479	2,127	3,165	3,206	3,197	2,870	2,875	3,547	3,658	3,429	3,271	3,555	3,672	3,462	3,663	3,645	3,551	3,971	6,106	3,590	3,821	3,989	3,993	4,199	4,890	5,089	4,313	4,403	5,526	6,110	5,182	5,181
Expenses	1,792	1,807	1,740	1,768	1,784	1,763	1,841	1,907	2,004	1,909	2,365	2,404	2,399	2,249	2,273	2,738	2,932	2,864	3,009	2,947	3,013	2,724	2,977	2,867	2,916	3,092	2,860	2,895	3,103	3,251	3,319	3,301	4,359	3,650	3,224	3,403	3,903	4,124	3,776	3,882
EBITDA	477	484	546	532	526	468	519	359	476	218	800	802	798	621	601	809	726	565	262	608	658	738	686	779	635	879	3,246	695	718	738	673	898	532	1,439	1,089	1,000	1,623	1,986	1,407	1,299
Operating Profit %	20 %	20 %	23 %	22 %	21 %	20 %	21 %	15 %	17 %	9 %	25 %	24 %	24 %	19 %	20 %	22 %	19 %	16 %	7 %	17 %	17 %	20 %	17 %	20 %	19 %	21 %	22 %	18 %	17 %	17 %	16 %	21 %	10 %	28 %	24 %	22 %	27 %	32 %	26 %	24 %
Depreciation	76	69	73	74	76	84	86	90	114	122	126	147	144	142	148	154	156	172	172	174	179	173	175	176	175	183	177	177	185	181	182	182	179	180	184	195	205	215	234	229
Interest	16	12	13	12	16	14	15	7	10	22	41	13	15	35	36	46	77	89	90	81	83	68	45	27	23	27	30	31	39	34	35	33	28	18	9	20	35	32	25	32
Profit Before Tax	426	519	545	537	498	441	435	324	412	154	712	722	724	570	535	672	606	394	122	457	522	588	524	617	526	777	3,135	598	558	673	648	781	484	1,328	1,006	947	1,550	1,900	1,271	1,184
Tax	69	51	60	97	-74	36	46	-6	20	9	200	168	125	102	107	150	124	69	28	86	108	102	89	89	-210	135	123	87	105	96	122	149	125	195	203	157	304	417	351	158
Net Profit	357	468	485	440	572	405	389	331	393	145	513	553	599	467	428	522	482	325	94	371	414	487	435	528	735	643	3,012	511	453	576	526	631	358	1,134	803	790	1,246	1,483	920	1,026
EPS in ₹	17.11	22.47	6.46	4.21	5.59	3.89	3.71	3.16	3.77	1.35	4.92	5.31	5.77	4.50	4.08	4.99	4.40	2.97	1.05	3.65	3.83	4.43	4.62	5.15	6.64	5.74	29.32	4.89	3.88	5.06	5.15	6.15	2.93	10.74	7.91	7.80	11.69	14.11	9.06	10.17

Show % Change

Above figures are in Rs. Crores

Balance Sheet

Balance Sheet	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	9,047	10,551	15,221	18,065	23,483	23,687	23,885	27,795	25,756	29,281
Fixed Assets	3,352	3,748	5,755	6,483	12,164	12,231	12,133	12,189	11,521	12,369
Current Assets	4,227	4,280	6,022	8,230	8,498	8,715	8,716	12,095	10,008	11,420
Capital Work in Progress	798	951	1,543	1,527	837	742	783	726	1,201	2,423
Investments	121	416	435	746	674	765	830	3,288	1,547	1,221
Other Assets	4,776	5,436	7,488	9,310	9,809	9,950	10,139	11,593	11,488	13,269
Total Liabilities	9,047	10,551	15,221	18,065	23,483	23,687	23,885	27,795	25,756	29,281
Current Liabilities	3,285	3,461	5,306	6,083	7,343	8,269	7,861	7,827	5,527	5,340
Non Current Liabilities	1,342	1,255	2,799	3,047	4,461	3,707	1,094	915	541	1,840
Total Equity	4,421	5,835	7,116	8,936	11,679	11,710	14,930	19,054	19,688	22,102
Reserve & Surplus	4,149	5,597	6,858	8,642	10,284	10,273	12,890	16,897	17,415	19,729
Share Capital	102	102	102	102	102	102	102	102	101	101

Show % Change

Above figures are in Rs. Crores

Cash Flow

Cash Flow	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Cash Flow	178	99	756	-3	-811	399	-91	219	-170	-75
Investing Activities	-465	-860	-2,872	-974	-3,977	-1,004	-837	-1,018	1,542	-1,492
Operating Activities	994	1,894	1,312	919	1,282	2,932	3,294	2,105	2,689	3,228
Financing Activities	-351	-935	2,316	52	1,885	-1,528	-2,548	-868	-4,400	-1,810

Show % Change

Above figures are in Rs. Crores

Share Holding

% Holding	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024
Promoter	74.88 %	74.88 %	74.88 %	74.88 %	74.88 %	74.88 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %
FIIs	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	5.72 %	5.59 %	7.52 %	7.53 %
DIIs	11.11 %	10.43 %	11.22 %	11.78 %	12.78 %	11.92 %	12.94 %	13.69 %	13.60 %	13.23 %	13.09 %	12.79 %	12.63 %	12.64 %	10.65 %	10.65 %
Government	0.19 %	0.07 %	0.07 %	0.07 %	0.08 %	0.08 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
Public / Retail	6.16 %	7.31 %	7.38 %	7.40 %	7.81 %	8.02 %	7.60 %	7.04 %	6.42 %	5.97 %	5.67 %	5.60 %	5.29 %	5.37 %	5.48 %	5.47 %
Others	7.66 %	7.32 %	6.44 %	5.87 %	4.46 %	5.11 %	4.48 %	4.29 %	5.00 %	5.82 %	6.26 %	6.63 %	1.38 %	1.43 %	1.37 %	1.36 %
No of Share Holders	0	2,23,384	3,31,155	3,51,595	3,70,931	4,08,017	4,55,624	4,08,231	3,70,396	3,11,764	2,97,953	3,06,495	2,94,324	3,36,309	3,70,863	3,65,356